In this Section |
252219 Evolution of a public health cancer screening programFriday, June 24, 2011
: 11:30 AM
The Affordable Care Act (ACA) will increase access to preventative cancer screening but building demand for services (public awareness), reducing barriers to screening, navigating clients through services and creating efficient health systems to carry-out the services will be essential to creating an effective cancer screening process. New York State Cancer Services Program has applied evidence-based activities, stringent fiscal monitoring and quality-oriented performance measures to initiate the evolution from a large, publically funded screening program to a population-based facilitator to efficient, quality screening under broader health insurance coverage.
Learning Areas:
Public health or related organizational policy, standards, or other guidelinesLearning Objectives:
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I have served as Director of the NYS Cancer Services Program since February, 2007. Prior to this role, I was the President/CEO of Gilda’s Club Capital Region NY. I relocated to the Capital Region of NYS in 2001 after serving as VP/COO of Western New York Physical & Occupational Therapy Group and in a variety of health care administrative and clinical roles in the WNY region.
I earned my B.S. in Physical Therapy from Russell Sage College, a M.S. from the Rochester Institute of Technology Executive Leader Health Systems Administration program and a post-graduate certificate in Palliative Care from the Institute of Palliative Care of The Sage Colleges. I am an adjunct instructor in the School of Business at Hudson Valley Community College and practice physical therapy at Physical Therapy & Wellness Solutions. I also provide leadership to a number of non-profit organizations in the Capital Region.
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 2004.0: Protecting Impacted Public Health Programs
|